Abraxis Bioscience, Inc. 10-Q Quarterly Report November 2009

The Independent Data Monitoring Committee For the ABRAXANE Non-Small Cell Lung Cancer Phase lll Clinical Trial has Recommended the Trial Proceed to Completion without Changes to the Sample Size

•

The FDA has Granted ABRAXANE Orphan Drug Status For the Treatment of Pancreatic Cancer and Stage IIb-IV Melanoma

•

Pivotal Phase lll Clinical Trials in Non-Small Cell Lung Cancer, Pancreatic Cancer and Melanoma Continue to Move Forward

LOS ANGELES, Calif. — November 5, 2009 — Abraxis BioScience, Inc. (NASDAQ: ABII), a fully integrated biotechnology company, today reported unaudited financial results for the third quarter ending September 30, 2009.

As of January 2, 2009, the company re-acquired the exclusive rights to market ABRAXANE^® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in the U.S. As a result, beginning in 2009, the company no longer recognizes deferred revenue related to the original co-promotion agreement.

Net revenue for the third quarter of 2009 was $96.6 million compared with $93.4 million for the third quarter of 2008. ABRAXANE revenue for the third quarter of 2009 was $82.9 million compared with $92.0 million for the same period in 2008, which included recognition of deferred revenue of $9.1 million related to the co-promotion agreement. Excluding the recognition of deferred revenue, total revenue from sales of ABRAXANE remained steady at $82.9 million for both the third quarter of 2009 and 2008. Other revenue for the third quarter of

(more)

The following information was filed by Abraxis Bioscience, Inc. on Thursday, November 5, 2009 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

Please wait while we load the requested 10-Q report or click the link below:

https://last10k.com/sec-filings/report/1409012/000119312509228040/d10q.htm

View differences made from one quarter to another to evaluate Abraxis Bioscience, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Abraxis Bioscience, Inc..

Continue

Assess how Abraxis Bioscience, Inc.'s management team is paid from their Annual Proxy

Abraxis Bioscience, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2009 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

CIK: 1409012
Form Type: 10-Q Quarterly Report
Accession Number: 0001193125-09-228040
Submitted to the SEC: Fri Nov 06 2009 9:56:59 PM EST
Accepted by the SEC: Mon Nov 09 2009
Period: Wednesday, September 30, 2009
Industry: Pharmaceutical Preparations

External Resources:

Bookmark the Permalink:
https://last10k.com/sec-filings/1409012/0001193125-09-228040.htm

Abraxis Bioscience, Inc. (1409012) SEC Filing 10-Q Quarterly report for the period ending Wednesday, September 30, 2009

SEC Filings

1409012 Annual Reports

1409012 Quarterly Reports

1409012 Corporate News